The Institute of Cancer Research has discovered a genetic mutation in samples of some men's tumours that could make them particularly susceptible to immunotherapy treatment. The researchers are now committed to running clinical trials to prove if their theory is right.
For the first time, more men are dying from prostate cancer each year than women are from breast cancer, making the male disease the third biggest cancer killer in the UK. We find out why and urge the public to help us raise the £120 million we need to curb the trend.
Hayley Yarnley knows how much our new precision medicine research programme could have helped her father, Bernie, who died from advanced prostate cancer last December. She describes how the births of her children kept him going during his treatment, and why he was convinced scientists would one day find a cure.
A new study suggests olaparib could boost the efficacy of treatment for earlier-stage prostate cancer, after discovering how it can block the repair of DNA in cancer cells no matter what kind of the disease they have.
New research funded by Prostate Cancer UK has discovered a blood test that can predict which men's cancer won't respond to certain hormone therapy, so they can pick the treatment that works for them while saving the NHS potentially huge sums on otherwise wasted drugs.
BLOG: We're only 12 months into our ten-year strategy to tame prostate cancer, but that doesn't mean we haven't already made exciting progress. Our resident expert, Dr Ian Le Guillou, gives us his top ten biggest research breakthroughs (in no particular order) from 2016.
Two research projects, using cutting-edge liquid biopsy technology to help improve diagnosis and treatment of men with prostate cancer, have been awarded funds by Prostate Cancer UK with the hope they'll used with real patients in the near future.
BLOG: With our new grants for research into the uses of liquid biopsies, Dr Sophie Lutter explains why they allow scientists to read clues about how a prostate cancer responds to treatment, and how they could revolutionise the way men are diagnosed and monitored with the disease.
New results from a clinical trial of olaparib suggest men with a common genetic fault could prolong their life after diagnosis by taking the pill twice a day.
Prostate cancers can run, but they can no longer hide. For the first time, researchers have found a way to target individual prostate cancer sites in other parts of the body. We take a look at the science behind this headline-grabbing story and ask if it lives up to the media fanfare.